Pulse stock rallies 22% on FDA breakthrough designation (NASDAQ:PLSE)
2024-07-08
designer491 Pulse Biosciences (NASDAQ:PLSE) stock rallied 22% in morning trading Monday after the medtech company said it had received FDA breakthrough device designation for its CellFX nanosecond pulse field ablation cardiac surgery system for the treatment of atrial fibrillation, or AFib. Pulse said it plans to pursue a premarket approvalContinue Reading